Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919581 · ClinicalTrials.gov registry record
Pilot Study: The Role of Macrophage Migration Inhibitory Factor (MIF) in Spinal Cord Injury
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 149
- Enrollment target
NCT00919581: Completed study, sponsored by Northwell Health.
NCT00919581 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 149 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00919581 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 149 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate inflammatory and other substances that may be elevated in the blood and blood cells following spinal cord injury (SCI). These substances will be evaluated in samples from people who have had a spinal cord injury due to trauma (e.g. car accident or a fall) within the first week (acute) or at least one year ago (chronic). Specifically, the study will evaluate the presence and levels of a protein, macrophage migration inhibitory factor (MIF). MIF is released by cells and has a specific effect on the way cells behave, communicate and work together. In several other medical conditions, MIF is known to increase inflammation in the body. By comparing blood samples from individuals with spinal cord injury and uninjured (no spinal cord injury) individuals, the investigators will try to find out if MIF levels are increased in people with SCI. Investigators will also use these samples to measure other proteins that increase inflammation in the body and to see if the biological activities of MIF can be reduced in a test tube by adding other substances to the blood samples. It is hoped that this study of MIF and other proteins related to inflammation will help improve the treatment of SCI in the future. We hope to enroll a total of 312 subjects in this study (50 with acute spinal cord injury, 125 with chronic spinal cord injury, and 137 uninjured individuals).
Primary Outcome
macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2009-05 |
| Est. Completion | 2016-12 |
What the finished NCT00919581 record still lists
NCT00919581 is an observational study that tracks outcomes without assigning an intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00919581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00919581 about?
NCT00919581 is a clinical study titled "Pilot Study: The Role of Macrophage Migration Inhibitory Factor (MIF) in Spinal Cord Injury". The purpose of the study is to investigate inflammatory and other substances that may be elevated in the blood and blood cells following spinal cord injury (SCI). These substances will be evaluated in samples from people who have had a spinal cord injury due to trauma (e.g. car accident or a fall) w...
What is the current status of trial NCT00919581?
This trial is currently completed. The enrollment target is 149 participants. The study started on 2009-05. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT00919581?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia